Long-term outlook
Gentian targets disease groups that represent a total addressable market of around USD 6.9 billion globally and an estimated growth rate of 5-10% annually over the next 3-5 years, according to leading market data provider Kalorama (2024, 2025). From a macro perspective, key growth drivers include a growing and ageing population contributing to an increase in chronic, non-communicable and infectious diseases globally.
The specific segments targeted by Gentian’s products add up to a total serviceable market of USD 1.9 billion (2025), with an estimated annual growth rate in line with the addressable market.
Gentian’s growth ambitions and revenue potential are set to be de-risked through several key milestones for the company’s product portfolio over the coming 12 months.
The key milestones are:
Established products
- Targeting additional large and medium-sized commercial partners globally
- Additional regulatory approvals, including IVDR, MDSAP and FDA to allow for commercial expansion
Market development
GCAL®
- To strengthen the clinical evidence base for GCAL® as a critical prerequisite for long-term market success.
- Securing endorsements from key opinion leaders and inclusion in clinical guidelines.
- Securing global commercial partnerships with phased regional rollout.
Product and pipeline development
- Progress in the undisclosed project through remaining development steps towards regulatory filing and commercialization by the exclusive partner in late 2027, pending regulatory timelines.
- Achieving proof-of-concept for several new pipeline projects.
- Continue investigations of high sensitivity technology.
- Gentian continues to strengthen its pipeline by aligning internal development and strategic collaborations with clear market demand and defined routes to commercialization.